• If you are wondering whether Revvity at around US$98.85 is offering value or is simply noise in your watchlist, this breakdown can help frame what the current price might be implying.
• The stock has been active recently, with returns of 14.1% over 7 days, 12.6% over 30 days, 0.7% year to date and 6.7% over 1 year, alongside longer term returns of a 15.8% decline over 3 years and a 29.2% decline over 5 years.
• These mixed returns indicate short term optimism combined with longer term caution, which can reflect changing views on the business outlook or on the reward for holding the stock. Even without a single headline event driving the move, such a pattern often prompts investors to reassess what they are paying relative to underlying fundamentals.
• Revvity currently has a valuation score of 3 out of 6. The next sections will walk through how different valuation approaches line up with that score and then finish with a broader way to think about valuation that goes beyond just the numbers.

Approach 1: Revvity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash Revvity could generate in the future and discounts them back to what they might be worth in $ today. It is essentially asking what those future cash flows are worth to you right now.

Revvity’s latest twelve month free cash flow is about $486.9 million. Analysts and internal estimates project free cash flow rising to $781 million by 2029, with a series of yearly projections between 2026 and 2035 that are based on both analyst inputs and extrapolations by Simply Wall St’s 2 Stage Free Cash Flow to Equity model.

When all those projected cash flows are discounted back and added up, the model arrives at an estimated intrinsic value of about $137.69 per share. Compared with the current share price of around $98.85, this implies a 28.2% discount. On this DCF view, the stock appears undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Revvity is undervalued by 28.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Revvity Price vs Earnings

For a profitable company like Revvity, the P/E ratio is a straightforward way to link what you pay for the stock to the earnings it currently generates. It helps you see how many dollars investors are willing to pay today for each dollar of current earnings.

What counts as a "normal" P/E ratio often reflects how quickly earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk can point to a lower P/E as more typical.

Revvity’s current P/E is 46.22x. That sits above the Life Sciences industry average of 36.52x and below the peer average of 67.04x, which already shows a wide range of valuations across similar stocks. Simply Wall St’s Fair Ratio for Revvity is 21.08x, which is its proprietary view of what the P/E might be given factors like earnings growth, profit margin, industry, market cap and risk profile. This Fair Ratio can be more tailored than a simple comparison with peers or an industry average, because it ties the multiple to Revvity’s own characteristics.

Against that Fair Ratio, Revvity’s actual P/E of 46.22x suggests the stock is trading on a richer multiple than that tailored reference point.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Revvity Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach a clear story about Revvity to the numbers you are seeing, by linking your view of its future revenue, earnings and margins to a fair value estimate that you can compare with the current price.

A Narrative on Simply Wall St’s Community page lets you spell out why you think Revvity might face regulatory headwinds and slower growth, which could point you toward a fair value closer to US$95.00, or why you think genomics, software and automation could support a stronger outcome, which lines up with a fair value closer to US$140.00.

Each Narrative ties that story to a full forecast, then calculates a fair value so you can quickly see whether your view suggests the stock is above or below what you think it is worth at today’s price. These Narratives are refreshed when new news, earnings or guidance are added, so your framework stays current without you needing to rebuild everything from scratch.

For Revvity however we will make it really easy for you with previews of two leading Revvity Narratives:

Fair value in this bullish Narrative: US$140.00

Implied discount to the Narrative fair value at the recent US$98.85 price: about 29.4%.

Revenue growth assumption used in this Narrative: 6.36%.

• Highlights Revvity's role in genomics and diagnostic automation, with newborn whole genome sequencing and lab workflow automation seen as key drivers of revenue and margin expansion.
• Emphasizes software ARR, 115% net retention and a SaaS shift that could support a higher recurring margin mix and stronger operating leverage.
• Builds in risks from regulation, funding pressures, competition and reliance on cost cuts and buybacks, and ties them to a US$140.00 analyst fair value that assumes higher revenue, margins and earnings by 2029.

Fair value in this cautious Narrative: US$95.00

Implied premium to the Narrative fair value at the recent US$98.85 price: about 4.0%.

Revenue growth assumption used in this Narrative: 5.34%.

• Focuses on regulatory shifts such as DRG related changes in China, healthcare cost controls and tariffs that could pressure diagnostics revenue and margins.
• Flags exposure to biopharma, diagnostics and constrained academic and government budgets, with softer capital equipment demand as a drag on earnings power.
• Assumes Revvity reaches US$3.3b revenue and US$697.2m earnings by 2029, but on a lower 16.6x P/E multiple, supporting a US$95.00 fair value that sits well below the bullish US$140.00 view.

If you want to see how other investors are framing the same facts and price, you can review the full range of community views on Revvity through See what the community is saying about Revvity.

Do you think there's more to the story for Revvity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.